What's Happening?
Telehealth providers in Michigan, particularly those offering peptide therapies online, are navigating a complex regulatory landscape governed by both Michigan's state telehealth laws and federal drug laws enforced by the FDA. While Michigan's laws dictate
how remote care is delivered, including requirements for informed consent, clinical evaluation, and adherence to the standard of care, federal regulations control what drugs can be prescribed, compounded, and sold. This creates a situation where compliance with one set of rules does not guarantee compliance with the other. For instance, a flawless telehealth visit does not legalize an unapproved product, and a lawful product does not excuse a deficient telehealth process. The FDA has recently focused enforcement on marketing claims for compounded products, challenging descriptions that imply approval, generic status, or equivalence to FDA-approved drugs. Additionally, the FDA has issued warnings against labeling products as 'for research use only' when promotional materials suggest human consumption.
Why It's Important?
This dual regulatory framework poses significant risks for Michigan medical practices and telehealth entrepreneurs. Licensed professionals, such as physicians and nurse practitioners, who serve as prescribers or medical directors for online peptide businesses, face potential licensing discipline under Michigan's Public Health Code for negligence, incompetence, or unprofessional conduct. They also risk federal liability for introducing unapproved or misbranded drugs into interstate commerce, which can lead to injunctions, seizures, or criminal enforcement. Furthermore, manufacturers of approved drugs may sue compounders and telehealth providers, and patients injured by products can file private claims. The lack of clear alignment between state and federal regulations creates legal uncertainty, potentially stifling innovation in telehealth while also exposing patients to unapproved or improperly marketed substances. This situation underscores the critical need for healthcare providers to meticulously verify product legal status, audit marketing claims, and ensure robust telehealth workflows.
What's Next?
Michigan telehealth providers are advised to take proactive steps to ensure compliance. This includes verifying the legal status of each peptide, confirming the authority of compounding pharmacies, and thoroughly auditing websites and advertisements to remove misleading claims. Practices must also build robust telehealth workflows that prioritize informed consent, sufficient clinical information gathering, and adherence to prescribing requirements. Additionally, clinicians must ensure they are licensed in the patient's physical location. Legal counsel is recommended for reviewing ownership structures and contracts, and for addressing any inquiries from regulators. The ongoing enforcement focus by the FDA on marketing claims for compounded products suggests that telehealth companies will continue to face scrutiny regarding how they present their services and products to the public. Future legislative or regulatory actions may seek to harmonize state and federal guidelines to provide clearer pathways for telehealth innovation while safeguarding public health.
Beyond the Headlines
The challenges faced by Michigan telehealth providers highlight a broader tension between rapid technological advancement in healthcare and the slower pace of regulatory adaptation. The rise of online peptide therapies, while offering convenience, also brings ethical considerations regarding patient safety and informed decision-making, especially when products lack full FDA approval. The 'research use only' loophole, often exploited by online sellers, underscores the need for clearer legal definitions and stricter enforcement to prevent the misrepresentation of substances intended for human use. This situation could lead to a re-evaluation of how new medical technologies and treatments are integrated into the healthcare system, potentially prompting calls for more unified federal and state oversight to protect consumers and ensure equitable access to safe and effective care. The legal complexities also raise questions about the liability of platforms that facilitate the sale of such products, potentially leading to new legal precedents in the evolving digital health landscape.













